Table 4

Propensity-Matched In-hospital Adverse Events in Female and Male PVI Patients

In-Hospital OutcomesMatched DataAll Data
Women
(n = 2,346)
Men
(n = 2,346)
p ValueWomen
(n = 5,105)
Men
(n = 7,274)
p Value
Death9 (0.38)5 (0.21)0.331 (0.6)28 (0.4)0.08
MI14 (0.6)7 (0.3)0.232 (0.6)35 (0.48)0.3
TIA/stroke5 (0.2)5 (0.2)1.011 (0.22)14 (0.2)0.8
MACE22 (0.9)14 (0.6)0.263 (1.2)65 (0.9)0.06
Transfusion164 (6.99)89 (3.79)<0.0001429 (8.4)309 (4.2)<0.0001
Vascular access complications105 (4.48)47 (2.00)<0.0001248 (4.9)152 (2.1)<0.0001
Embolic complications27 (1.15)10 (0.43)0.00540 (0.8)24 (0.3)0.0005
Thrombotic complications17 (0.72)21 (0.9)0.552 (1.0)49 (0.7)0.04
Amputation103 (2.0)134 (1.84)0.447 (2.0)42 (1.8)0.6
Lesions not crossed64 (2.73)87 (3.71)0.057302 (5.9)587 (8.07)<0.0001
Technical success2,140 (91.22)2,090 (89.09)0.0143,993 (86.9)5,578 (84.5)0.0004
Procedural success1,870 (79.7)1,916 (81.67)0.083,456 (75.2)5,107 (77.4)0.008
Length of hospital stay, days
 Mean ± SD1.92 ± 3.61.69 ± 3.192.15 ± 3.981.76 ± 3.37
 Median (Q1, Q3)1 (1, 1)1 (1, 1)<0.00011 (1, 1)1 (1, 1)<0.0001

Values are n (%) unless otherwise specified.

MACE = major adverse cardiovascular event(s); MI = myocardial infarction; PVI = peripheral vascular intervention; TIA = transient ischemic attack.

  • Patient characteristic variables that were used for matching are age, estimated glomerular filtration rate, coronary artery disease, diabetes, hypertension, hyperlipidemia, congestive heart failure, chronic obstructive pulmonary disease, anemia, body mass index categories (lean, overweight and obese), claudication, critical limb ischemia, vascular bed location (aortoiliac, femoropopliteal, and below knee), and pre-procedural medication usage (angiotensinogen inhibitors, β-blockers, heparin, low molecular weight heparin, warfarin, diuretic, bivalirudin, eptifibatide/tirofiban, lipid-lowering drug, antiplatelet therapy).